[Featured Stock] Jinwon Life Sciences Soars on Approval of Oral COVID-19 Treatment Phase 2 Trial

[Asia Economy Reporter Lee Seon-ae] The stock price of Jinwon Life Sciences is showing a sharp rise.

As of 9:42 AM on the 1st, Jinwon Life Sciences' stock price is trading at 27,550 KRW, up 9.98% compared to the previous trading day. It surged to 29,300 KRW at the start of trading. The surge is attributed to the news that the Phase 2 clinical trial plan for the oral COVID-19 treatment candidate 'GLS-1027' (International Nonproprietary Name: Genuzolac), developed by Jinwon Life Sciences, has been approved by the European Medicines Agency (EMA) and Bulgaria.

This Bulgarian clinical trial is part of the global Phase 2 trial of GLS-1027 involving 132 patients with moderate COVID-19 across five countries. Jinwon Life Sciences had previously received clinical trial approvals in the United States, South Korea, North Macedonia, and Puerto Rico. Jinwon Life Sciences plans to evaluate the efficacy of GLS-1027 in preventing symptom worsening by administering it to hospitalized COVID-19 patients at a total of 12 institutions.

Park Young-geun, CEO of Jinwon Life Sciences, stated, “This is the first case of our company receiving Phase 2 clinical trial approval from the EMA, marking a very important milestone as the target for domestic sales and global marketing will expand not only to the United States but also to Europe.” He added, “Since Bulgaria is experiencing the third wave of COVID-19, recruitment of subjects for the multinational clinical trial of GLS-1027 will proceed rapidly.”

This content was produced with the assistance of AI translation services.